Portsmouth Hospitals University NHS Trust
Portsmouth, Hampshire, PO6 3LY, United Kingdom
Location status: Recruiting
NCT Number: NCT07613593
This study will provide valuable insights into the demographics of MyRenalCare users, their digital adherence, and the overall impact of the app on health outcomes, healthcare costs, and environmental sustainability.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Portsmouth, Hampshire, PO6 3LY, United Kingdom
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
5.1.1 Inclusion criteria - MyRenalCare users (retrospective and prospective cohorts)
Adults will be eligible for inclusion in the MyRenalCare cohorts if they meet all of the following:
Specific CKD stage definitions and thresholds (e.g. based on eGFR, albuminuria or uPCR) will be documented in the study manual to ensure consistent application.
5.1.2 Inclusion criteria - matched usual care controls
Adults will be eligible for inclusion in the matched control cohorts if they meet all of the following:
Controls will be identified retrospectively from the renal electronic patient record and matched to MyRenalCare users using a predefined matching strategy.
5.1.3 Inclusion criteria - qualitative interview participants (patients and staff)
Patients will be eligible to take part in the qualitative interview component if they meet all of the following:
Clinical staff will be eligible if they meet all of the following:
Exclusion criteria
Study is non-interventional.
Other names: non-interventional
Time frame: 12 months
Outcome measure 1: Number and proportion of MyRenalCare users by age, sex, ethnicity and Index of Multiple Deprivation quintile, compared with the CKD population under Wessex Kidney Centre care. Prevalence ratios will also be calculated.
Time frame: 12-months
Outcome measure 2:
Composite digital adherence score (0-100) for MyRenalCare users, combining log-in frequency, completeness of blood pressure and symptom entries, use of secure messaging and duration of sustained use. Analyses stratified by age, sex, ethnicity and deprivation.
Time frame: 12-months
Outcome measure1: Number of unplanned and planned hospital admissions for MyRenalCare users compared with matched usual-care controls.
Time frame: 12-months
Outcome measure 2: Number of outpatient visits (renal and non-renal) for MyRenalCare users compared with matched usual-care controls.
Time frame: 12-months
Outcome measure 3: CKD progression, measured by change in eGFR, movement between CKD stages, and initiation of kidney replacement therapy for MyRenalCare users versus matched controls.
Time frame: 12-months
Outcome measure 4: NHS healthcare costs per patient-year for MyRenalCare users compared with matched usual-care controls, including inpatient, outpatient, emergency and relevant community or virtual care contacts.
Time frame: 12-months
Outcome measure 5: Estimated patient travel-related CO₂ emissions for renal care appointments for MyRenalCare users versus matched usual-care controls, based on travel distance and mode.
Time frame: 12-months
Outcome measure 6: Themes from qualitative interviews with patients and staff on MyRenalCare usability, support needs, barriers and facilitators to digital engagement.
Contact information is provided by the study sponsor or research team.
Portsmouth Hospitals NHS Trust
Other Gov
Acronym: INCLUDE-CKD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06329622
Atrophy, Chronic Disease
Shanghai, China
View Trial DetailsNCT07107945
Chronic Disease, Chronic Kidney Disease
Birmingham, Alabama, United States
View Trial DetailsNCT07153939
Arteriovenous Fistula, Arteriovenous Malformations
Dothan, Alabama, United States
View Trial DetailsNCT07729683
Chronic Disease, Chronic Kidney Disease
La Rochelle, France
View Trial Details